HER2 Breast Cancer

Trastuzumab is a monoclonal antibody that has been engineered to attack and block the human epidermal growth factor receptor 2 (HER2), a protein that contributes to cancer cell growth. It is used most frequently to treat HER2-positive breast cancer and HER2-positive gastric cancer. As a targeted agent, trastuzumab has greatly enhanced treatment outcomes for patients with tumors that overexpress HER2. Mechanism of Action Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to the extracellular domain (subdomain IV) of the […]